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Abstract T cells in tumors—the so-called tumor infiltrating
lymphocytes (TIL) have been studied intensively over the
past years. Compelling evidence point to a clinical relevance
for high numbers of T cells at the tumor site with CD8
memory T cells as a key denominator for overall survival
(OS) in patients with colo-rectal cancer (CRC), and also for
others solid cancers. These data goes hand in hand with
studies of clonality of TIL showing the T cells among TIL
are expanded clonally, and also that tumor specific T cells of
CD4 as well as CD8 type are enriched at the tumor site. The
tumor microenvironment is hostile to T cell function e.g.,
due to expression of enzymes that depletes the amino acids
tryptophan and arginine, high concentration of tumor secret-
ed lactate, and presence innate cells or regulatory T cells
both with suppressive activity. Analyses of the specificity of
TILs in melanoma demonstrate that quite few known anti-
gens are in fact recognized by these cultures underscoring
patient unique and/or mutated antigens may represent im-
portant target for recognition.
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Introduction
Tremendous focus has been on elucidating the biological
properties of cancer cells. To this end, for many cancers we
have detailed information on the genetic and epi-genetic
alterations in the cancerous cells and the associated changes
in signaling pathways, cell cycle regulation, etc. However, it
has also become realized that the tumor is a complex entity
comprising cancer cells and stromal cells, tumor infiltrating
cells—both cells of the immune system and cells not by
convention being of the immune system, as well as an
extracellular matrix mainly of proteins and carbohydrates.
Strikingly, cancer cells may comprise as little as approx.
30 % of the cells in the tumor. Moreover, cancer cells are in
most cases not autonomous—they need stroma cells to
survive and grow, which in turn implies that non-
cancerous cells in the tumor have an intimate relationship
to the cancer cells. The intra-tumor cell types may play
various roles in the natural life of the tumor, being
pro-tumorigenic or the opposite. In this part we discuss
the role of CD4 and CD8 effector T cells in the tumor
microenviroment.
Tumor Infiltrating Lymphocytes in Solid Tumors
and Impact on Course of Disease
Mainly using immune histochemistry (IHC), the presence of
T cells in tumor biopsies and their potential impact on
prognosis have been studied for decades. Early data sug-
gested that a brisk infiltration of T cells in primary melano-
ma lesions was a positive prognostic factor [20]. More
recently similar data has been found in other cancers includ-
ing ovarian cancer [92], renal cell carcinoma (RCC) [73],
bladder cancer [96], and several other solid cancers. Obvi-
ously, this goes well hand in hand with the data now avail-
able on the presence of tumor specific T cells among TIL as
discussed in more detail in later sections. As given above the
main incentive for studying T cell infiltration has been to
identify any impact on clinical course. However, when it
comes to a potential clinical significance many studies are
rather small and thus of limited statistical strength. In a
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recent meta-analysis including studies in which clinical
significance of TIL were studied in solid tumors (CD3,
CD4, CD8, FoxP3 and rations between these), the presence
of CD3, CD8, as well as a high CD8/FoxP3 ration had a
positive effect on survival [44]. In addition, the assessment
of TIL density and distribution was shown to independently
predict sentinel lymph node status and survival in patients
with melanoma [10]. Some studies have been more detailed
in term of T cell subtypes and the compiled data described
by Fridman and colleagues show that CD8/CD45RO and
Th1 T cells are both found to be a positive prognostic factor
in the vast majority of studies [36]. Thus, memory T cells
and/or T cells with a Th1 biased phenotype are associated
with a better prognosis. To this end, Galon and colleagues
have studied approx. 400 patient samples and shown that
CD8, CD45RO T cells in the core of the tumor is a superior
prognostic factor to the conventional clinical staging in
colorectal cancer [39]. Strikingly, even patients with local-
ized disease had a very poor prognosis, similar to that of
patients with concomitant distant metastasis if their tumors
showed low frequency of T cells in the tumor core. Thus,
overall survival of these patients is governed to a large
extent by the local adaptive—and supposedly tumor
specific - immune response. Obviously, this underscores
that the quantity and quality of T cells participating is key,
with CD45RO T cells being crucially important. Moreover,
the capacity of the T cells to infiltrate deep into the core of
the tumor is fundamental in terms of anti-tumor activity that
translate into benefit in survival benefit [36].
Although there have now been conducted numerous
studies that suggest a positive prognostic impact of TIL,
some of which are quite large, this still need to be verified
in large multi-center studies recently initiated [40]. Provided
that the data from this study support the impact of immune
infiltrating cells in CRC lesions, this will completely change
the prognostic tools in this disease to the benefit of the
patients. To this end, quite a substantial fraction of patients
with local spread of disease are treated with chemotherapy.
However, available data suggests that most of these patients
have a very limited risk of relapse if the tumor has a
pronounced infiltration of memory T cells in the tumor core.
As mentioned, other cancers have been studied as well, and
if the prognostic impact of T cell infiltration is verified in
CRC there is no question that similar studies will be
conducted in other indications.
At present there is very limited knowledge as to why
some tumors are heavily infiltrated by T cells whereas others
are not. Very elegant studies in murine models from the lab
of Robert Schreiber have suggested the “Three Es of cancer
immunoediting” - that the interplay between tumor and the
immune system goes through three phases characterized by
immune-elimination (of cancer cells), immune equilibrium
(between cancer cells and cells of the immune system) and
immune escape (by cancer cells). Along those lines, it could
be speculated that some lesions progress faster and reach the
“escape” phase even as a primary or early metastatic tumors
[30]. However, the notion of the “Three Es of cancer immu-
noediting” and its relevance in human tumor immunology is
still unclear. Moreover, such very rapidly progressing
lesions would still have a biological background. To this
end, one would expect that the induction of a clinically
relevant T cell response - capable of extending the life-
expectancy of the patients, is induced via cells of the innate
immune system. Consequently, the quality and quantity of
the induced response may be influenced by numerous fac-
tors in the micro-environment of the tumor and the draining
lymph nodes; cytokines and chemokines in turn influencing
the cell types attracted and their function, availability of
nutrients, oxygen, lactate, expression of danger signals,
etc. Quite likely, a rational approach to reach a higher level
of understanding of these important issues will require a
systems biology approach with large numbers of patient’s
samples with associated clinical data to be studied at the
genomic, proteomic, molecular, and cellular level and the
collected data to be integrated. The data may provide us
with tools that enable the therapeutic transition of a tumor
from a “non-inflammatory” to an “inflammatory tumor”
with the associated impact on overall survival. Moreover,
although T cell infiltration into tumors may have a signifi-
cant impact on patient survival, most cancer patients with
metastatic disease eventually die from their cancer, which
underscores that elucidation of the mechanisms of immune
escape may lead to development of new strategies that
extend the immunological control of tumor progression.
It remains to be seen if T cells—as suggested by the
available data so far – are important players in the majority
of solid cancers. To this end, in renal cell carcinoma (RCC)
some data suggests that TILs is only a good prognostic
factor if the cells are proliferating [73]. In pancreatic cancer,
immune therapy with agonistic CD40 antibody was shown
to be depended on macrophages rather than the expected T
cells [12]. Thus, each organ is characterized by unique
immune characteristics and similarly each tumor entity is
likely to possess unique infiltrates of immune cells.
This proposed clinical impact of CD8 T memory cells
among TIL is striking and obviously suggest their in situ
function to be direct cancer cell killers. Accordingly, our
current knowledge suggests that CD8 T cells seem to be
more “simplified” in function compared to the CD4 T cells,
and the reason for a stronger consensus in clinical signifi-
cance lies in the fact that the presence of a simple killer at
the tumor site really only have one outcome. However, it
should be kept in mind that suppressor CD8 T cells have
been described. These CD8 suppressors detected in quite
high frequencies in cancer patients were characterized by
very potent suppressive capacity, and the detection of such
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cells at the tumor site could therefore reveal yet another
layer of complexity [6]. Unfortunately, there are as of yet
no surface markers that enable IHC of these cells.
As given above data are accumulating that point to a role
of CD8 T cells in spontaneous tumor control. Available data
on CD4 T cells are more dubious, which could be taken as
support for the notion that CD4 T cells are more plastic and
play dual roles; thus CD4 T cells can convert from anti-
tumor to pro-tumor [95, 111]. Moreover, concerning Treg
some organs are characterized by large numbers of Treg,
underscoring the role of the tissue in immune responses as
recently suggested by Polly Matzinger [67]. Herein lies
probably the reason that prognostic significance of CD4 T
cells—irrespective of subtype—is controversial despite nu-
merous and quite large studies [36]. Early data in studies of
Treg mainly studied the expression of CD3 FoxP3 cells
alone. However, more recent studies include staining for
CD8 as well and the ratio of these cell types have been
shown in numerous studies to be significant, with more
CD8/few FoxP3 being described as a positive prognostic
factor in many studies. Thus, despite the fact that FoxP3
may not be expressed solely by Treg these data does suggest a
predominant expression of FoxP3 in cells that are pro-tumor.
CD4 T cells will in many cases not be able to recognize
cancer cells directly due to the lack MHC class II on most
(solid) cancers. Obviously, hematological cancer represents
an exception since many cell types of the immune system
may express class II molecules e.g., B and T cells. However,
solid cancers may express class II molecules constitutively,
such as over 40 % of melanomas [68] or upon induction
with IFN-g. In addition, TILs in melanoma, breast and
ovarian cancer comprise CD4 T cells specific for class II
restricted tumor antigens [25, 26, 88]. CD4+ T cells may
indeed exert anticancer actions by providing help to CD8+ T
cells or, in some cases, directly recognizing endogenously
processed antigens presented on the surface of cancers
eventually followed by secretion of type 1 cytokines [27,
37] or direct tumor killing [86] To this end, a CD4 T cell
clone specific for a class II restricted NY-ESO-1 peptide
mediated anti-tumor function when administered to a mela-
noma patient [50] and some patients undergoing TIL based
adoptive T cell therapy with infusion products largely
dominated by CD4+ T cells nonetheless obtained clinical
regressions either in our trial [clinicaltrials.gov identifier :
NCT00937625] or elsewhere [15, 84]. Along this line of
research, Friedman and colleagues have studied 44 cultures
of CD8 depleted TILs and found that 8 of these (18 %)
secreted IFN-γ that could be blocked by class II antibody
upon co-culture with autologous established melanoma cell
lines or fresh tumor digests. In another study, we have
detected specific production of two type 1 cytokines
(TNF-α and IFN-γ) by CD4+ T cells in 6 out of 12 TILs
(50 %), upon co-culture with autologous short-term cultured
melanoma cells in which class II expression was pre-
induced by IFN-γ [27]. Thus, these data point out that a
significant fraction of tumors are indeed naturally infiltrated
by CD4 T cells which are tumor specific and class II re-
stricted. However, their function is hard to scrutinize due the
more plastic nature of these cells—and the lack of appro-
priate markers to identify different subsets.
Clonally Expanded T Cell Clonotypes Among TIL
T cells recognize peptide antigens in the context of MHC
molecules through the clonally distributed T-cell receptor
(TCR). Accordingly, activation of a T cells and the subse-
quent proliferation leads to elevated numbers of mRNA
encoding that particular TCR alpha and beta chains. Thus,
detection of expanded TCR clonotypes is a strong indication
that an HLA restricted T-cell responses is ongoing [74, 106].
A limited number of studies have been conducted in various
murine tumor models e.g. the widely used murine melano-
ma model B16. T cells infiltrating B16 tumors were shown
to comprise numerous clonal TCR transcripts none of which
could be recurrently found in different animals [70]. Even in
different tumors in the same animal most TCR clonotypes
are unique i.e. none-public at least concerning spontaneous
responses [70]. In a study in which IL-2 was targeted to the
tumor site identical TCR clonotypes could be found infil-
trating tumors on both flanks of the animals, even if only
one tumor had been targeted with IL-2 [102, 104]. Thus, at
least during therapy T-cell clonotypes may travel across the
blood stream and home to distant tumor sites.
In human tumors data from several studies demonstrate
that TILs are clonally expanded. To this end, the presence of
expanded T-cell clonotypes have been demonstrated in mela-
noma [101, 103], and these findings have been corroborated
by others and – importantly – also been found in other cancer
lesions, e.g., seminoma and breast cancer [107].
Melanoma has been most intensively studied, and at least
as judged by the more limited data available from studies of
other cancer biopsies, melanoma seem to be characterized
by an exceedingly high number of clonally expanded T
cells. Thus, subcutaneous lesions may comprise up to 60
or 80 unique expanded T cell clonotypes [103]. This sup-
ports the notion of an ongoing anti-tumor immune response
in situ, however, standing alone these analyses are merely
descriptive and reveals no insight into the type, function and
specificity of the T cells.
The clonal distribution of the TCR offers the means to
detect and track specific T cells based upon detection of the
unique TCR. In this respect, identical TCR clonotypes can
be detected in different lesions from the same patient and
treatment induced responses can be tracked to the tumor site
from the blood [3]. Also, in some studies it has been
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possible to track T-cell clonotypes from the tumor even
before vaccination and monitor the clonotype upon treat-
ment both in blood and tumor site [13]. Similarly, TCR
clonotype analyses may shed light on the TIL in situ and
after in vitro growth. To this end, we have shown that
although clonotype composition may change during culture
[105] the use of high-dose IL-2 for expansion of TILs for
adoptive transfer seem to maintain a substantial fraction of
in situ TIL clonotypes during expansion, and as a conse-
quence studies of IL-2 expanded TILs bear relevance for the
TILs in situ at least in terms of specificity [54].
The specificity of TIL will be discussed in some more
detail below, but in a number of studies the connection
between clonality and specificity has been verified providing
evidence that the clonally expanded cells at the tumor site may
indeed be tumor specific. Thus, clonal responses against the
HLA-A2 restrictedmelanocyte differentiation antigenMART-
1 has been studied in detail with respect to clonotype compo-
sition [91, 110], and Ferradini and colleges characterized a
cytotoxic T-cell clone derived from the regressive part of a
melanoma tumor, however the antigen was not characterized
[34]. The general findings of such studies is that responses
may involve numerous TCR clonotypes, and although there
may be structural similarities, quite different TCRs may re-
cognize the same HLA/peptide complex [65, 89].
Specificity and Function of TIL
We and others have also used IHC with specific HLA-
peptide multimers to demonstrate the presence of tumor
specific T cells at the tumor site, e.g., using multimers to
detect CD8 T cells specific for Mart-1, survivin and HO-1
[4–6]. Indeed using confocal microscopy it was possible to
demonstrate that specific cells also expressed markers asso-
ciated with cytotoxic activity suggesting in situ tumor cell
killing. Others have used a different approach and taken
advantage of needle biopsies to demonstrate an enrichment
of tumor specific CD8 T cells intratumorally compared to
peripheral blood [61, 62, 77, 78]. These data demonstrate
that numerous antigens are recognized by melanoma TIL
and also that these antigens fall in different groups. Thus,
although it seems that differentiation antigens gp100 [11]
and Mart-1 [57] are quite dominant, cancer testis antigens
[21], over expressed antigens [2], and mutated antigens are
recognized as well [115].
CD8 T Cells in Melanoma—Lessons from in vitro
Expanded TIL Cultures and Their Clinical Application
CD8 T cells among TILs have shown great promise when
used for ACT in melanoma [90]. This therapy has been
pioneered by the group of Steve Rosenberg at NIH and is
currently established in a small number of cancer-centers
worldwide [14, 32, 87]. TILs are cultured from resected
melanoma lesions and after in-vitro expansion in the pres-
ence of IL-2 transferred back to the lymphodepleted patient
together with supplement IL-2 treatment. As given above, in
situ TCR clonotypes are maintained during the expansion
and studies of these cultures may therefore provide valuable
new knowledge with regards to the antigens recognized and
the therapeutic potential of the cells.
The Antigen Specificities Recognized by Melanoma Tumor
Infiltrating Lymphocytes
Melanoma TILs used for adoptive cell therapy has shown
both autologous and allogenic tumor cell recognition, but
until recently very little was known about the antigen spe-
cific reactivity of these TIL preparations. Two publications
by Andersen et al. [7] and Kvistborg et al. [60] have recently
demonstrated that TILs comprise T cells reactive against
only a minor fraction of the previously described T-cell
epitopes relevant for melanoma. Moreover, most identified
peptide-specific T-cell populations were of quite low fre-
quency (< 1 % of total CD8+ T cells). In these studies,
melanoma TILs were screened for reactivity against a
library of all published T cell epitopes of relevance for
melanoma, including 175 MHC-class I peptides restricted
to HLA-A1, A2, A3, A11 and B7 [7]. Screening of
peptide-specific T-cell responses was conducted by MHC-
multimers, generated by peptide exchange from conditional
ligand-HLA complexes and combinatorially encoded with
different fluorescence molecules to generate unique two-
color codes allowing parallel detection of large numbers of
different antigen specific T cells [46, 108]. Based on TILs
from three different centers data from these studies showed
that T-cell populations recognizing described T-cell epitopes
are low-frequentcy and only a small fraction of the de-
scribed melanoma-associated antigens are indeed recog-
nized. The most prominently recognized groups of
antigens were differentiation antigens, with MART-1 and
gp100 together accounting for more than half of the
responses. Cancer-testis antigen-responses were also ob-
served, but strikingly few epitopes from the group of over
expressed antigens were recognized, and the majority of
these were encoded in alternative open reading frames
(ORFs).
An obvious limitation in our knowledge about T-cell
recognition relates to the HLA-restriction of the described
epitopes. In the database generated of all described tumor
associated T-cell epitopes 57 % of all epitopes (326 of 576)
are restricted to HLA-A2. Although this allele is frequently
expressed in many different population, even for an HLA-
A2 positive individual the responses determined by the
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additional 5 HLA class I loci may be of equal importance for
the tumor recognition as the HLA-A2 restricted recognition.
Recognition of de-novo Sequences/Mutated Antigen
There is no question a significant number of tumor associ-
ated antigens remains to be identified. An important group
of antigens, not included in from the study described above
is the personalized de-novo epitopes—antigens arising from
mutations in the individual tumor. It has recently been
demonstrated in mice that mutated antigens may be a target
for immune recognition, with the potential to eradicate a
developing tumor [66], and that the growing tumor undergo
an immunoediting process, including changes in the muta-
tion pattern, and thereby may escape immunological recog-
nition [31]. Based on these data, it could be speculated that a
large fraction of the tumor reactive CD8 T cells among TILs
recognize specific mutations formed in the individual
patient’s tumor.
Since the mutation landscape of human tumors is very
diverse, a personalized approach may be required to de-
scribe the entire range of T-cell reactivity against mutated
antigens. The vast majority of mutations found in human
tumors is patient specific and will differ among different
patients, even with the same cancer type. Furthermore, there
may even be differences among lesions from the same
patient, as well as intra-lesional heterogeneity [42]. It has
been documented that mutated sequences may be recog-
nized by the immune system and that these can be thera-
peutically targeted to induce efficient anti-tumor reactivity
even in tumors developed in an immunocompetent host [18,
63]. Also among TILs used for adoptive cell therapy recog-
nition of mutated sequences has been described [116]. I has
been predicted that a large number (~8000) of HLA-binding
peptides may exists around functionally relevant missense
mutation sites with significantly increased HLA-binding
affinity of the mutated peptide versus the cognate wildtype
peptide. This would imply that a large number of peptide
sequences not present in normal cells may be presented to
the immune system as a consequence of mutations in
tumors. Since these sequences are foreign to the patient’s
immune system, they serve as ideal targets for T-cell recog-
nition, as the repertoire of T cells recognizing these are not
limited by tolerance, as is often the case with peptide
sequences from shared antigens.
TILs in Non-melanoma Solid Cancers and Potential
Clinical Application
In ovarian cancer, infiltration of CD3 and CD8 T cells is of
prognostic significance as evident in a recent meta-analyses
[51]. Further supporting the importance of a stimulatory
intratumoral T-cell response, regulatory cell populations
has been correlated with poor clinical outcome in ovarian
cancer, such as Tregs [22] and immunosuppressive B7-H4
expressing macrophages [59]. Also, and PD-L1 expression
and overexpression of the endothelin B receptor (ETBR) on
ovarian cancer cells is correlated to decreased numbers of
tumor infiltrating lymphocytes, and associated with poor
prognosis [48]. For these reasons, TIL adoptive transfer as
a therapeutic approach may seem obvious in ovarian cancer,
and a number of pilot clinical trials support the feasibility of
adoptive TIL therapy for ovarian cancer [55].
Renal cell carcinoma is one of the additional tumors
considered immunogenic and with proven clinical benefit
for immune modulatory treatments such as IL-2 or PD1 and
CTLA-4 blockade [16, 28, 49, 109], however tumor-
infiltrating lymphocytes has not yet proven feasible for
adoptive T cell therapy in this disease. RCC TILs comprise
effector T cells alongside regulatory T cells [9], and some
data suggest that T cells in RCC TILs may differ from
melanoma in being more differentiated and exhausted, sug-
gesting that other means of culturing may be required to re-
activating and expansion of RCC TILs in vitro [112].
We recently studied the clonotype composition in RCC
and strikingly, most lesions studied were characterized by
absence or very few clonally expanded T cells (Sittig et al.
Manuscript in preparation). RCC is a more vascularized
tumor than e.g., melanoma for which reason blood T cells
may be a more prominent component of the TILs. However,
as judged by phenotype analyses these TILs are very differ-
ent from PBMC T cells e.g., by expression of PD-1 in a high
frequency suggesting that these are not simply PBMC T
cells. Moreover, it seems that cytoxicity even against autol-
ogous tumor cell lines is rarely detectable [8].
Head and neck squamous cell carcinoma (HNSCC) com-
prise TILs and it has been shown that TILs in HNSCC may
be capable of killing autologous HNSCC cells [47]. We
recently conducted a pre-clinical study on HNSCC TIL
and demonstrated that these can be expanded with high dose
IL-2, and were capable of killing autologous as well as
allogeneic tumor cell lines [54]. Although not tested in the
clinic these data suggests that ACT in HNSCC using TILs
could be clinically relevant.
Phenotypes of Tumor Infiltrating Lymphocytes
and Manipulation of Immune Checkpoints
Tumor infiltrating T cells may display a wide range of
different phenotypes. In general, however, several studies
have shown that CD8 T cells at the tumor site display
markers of T cell exhaustion to a higher extend than do T
cells in the blood or T cells from normal adjacent tissue [1,
112]. In melanomas CD8 tumor infiltrating T cells display a
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high expression of PD1 and CTLA-4, and are often co-
expressing these inhibitory molecules. At the same time
they have a high expression of HLA-DR, a marker for T
cell activation and low expression of CD127, the IL-7
receptor alpha chain, as well as CD25 [1]. Also CD4 T cells
showed high expression of the immune inhibitory molecules
PD1 and CTLA-4. Furthermore it was evident that the PD1
positive fraction of the TILs display impaired effector func-
tions [1]. Also in prostate cancer, PD1 is significantly
expressed by CD8 TILs [94], and this marker has shown
prognostic value in breast cancer [43], as well as in several
other cancers as indicated above. Recent studies in breast
cancer patients show evidence of exhaustion in both blood
and tumor already at early stage disease, with upregulation
of PD1 and CD69. With disease progression exhaustion
became even more evident and TILs displayed more termi-
nally differentiated markers than T cell from peripheral
blood [85]. Thus, it appears that the tumor induce a general
immune suppression already at very early stage of disease.
The immune regulatory checkpoint PD1 and CTLA-4
play a major role in the exhausted phenotype of TILs, and
blockade of these has shown to not only increase effector
functions but also increase infiltration into tumor lesions
[23, 24]. One mechanism by which PD-1 blockade may
promote tumor-infiltration as through increased levels of
IFN-γ inducible chemokines [82]. Also PD-L1, which is
primarily expressed by tumor cells or tumor associated
fibroblasts, may regulate T-cell infiltration. PD-L1 expres-
sion has been correlated with decreased CD8 infiltration, but
the correlation to overall survival or disease progression
remains controversial and may differ with regard to different
malignancies [19, 38, 41]. However, overall there is clear
association between the manipulation of these immune-
blockade pathways, increased T-cell functionality, increased
tumor infiltration and the clinical effect of these novel
immunotherapies.
T Cell Functionality in the Hostile Tumor
Microenviroment
As described elsewhere T cells may express inhibitory sur-
face molecules the blockade of which may lead to clinically
relevant anti-tumor T-cell responses. A detailed description
of local tumor suppression of T cell function is beyond the
scope of this review and a number of mechanisms may be at
plays that render T cells in tumors non-functional. As al-
ready mentioned Treg may play a role in inhibiting CD8 T
cell responses by various mechanisms [22], and MDSC and
other cells on the innate immune system may play a similar
role [28, 69, 76, 93]. For instance, expression of the
enzymes Indoleamine-2,3-dioxygenase 1 (IDO-1) [72],
IDO-2 or tryptophan 2,3-dioxygenase (TDO) [114], or
tryptophan hydroxylase-1 [75] all metabolize tryptophan
and thereby deplete Trp in the microenvironment. These
enzymes may be expressed by cancer cells or by cells of
the innate immune system; e.g. dendritic cells. Interestingly,
we recently identified IDO derived peptides to be recog-
nized by cytotoxic T cells in cancer patients suggesting a
counter response against cells expressing immune suppres-
sive IDO [97–100]. Arginine (Arg) may be depleted at the
tumor site similarly due to expression of arginase-1 which is
expressed by myeloid derived suppressor cells (MDSC)
[17]. Lack of the amino acids Trp and Arg leads to activa-
tion of the GCN2 signaling pathway [71] which renders the
T cell non-functional and eventually the T cell will go into
apoptosis. Other cell types—including cancer cells express
the IMPACT protein which is inhibiting GCN2 signaling
thereby leaving these cells more resistant to amino acid
deprivation [45].
Cancer cells are characterized by an altered metabolism –
glycolysis – which metabolize glucose to lactate which is
secreted to the microenvironment rather than further metab-
olized in the mitocondria. This altered metabolism is gov-
erned by activated oncogenes and/or hypoxia. Lactate
impact negatively on the function of cells of the immune
systems and lactate is detrimental to T cell function; cyto-
kine production and cytotoxic capacity [29, 35].
Several other mechanisms have been described. To this
end, some cancer cells secrete cytokines that are directly
immune suppressive e.g., interleukin 10 and Transforming
growth factor β (TGF-β), or cytokines that attract cells that
diverge the anti-cancer immune response in a more pro-
tumor direction (e.g., interleukin 6 and 8, and thymic
stromal lymphopoietin (TSLP)) [81].
T Cell Infiltration in Virus Induced Cancers
Several types of cancers are known to have a viral origin.
These include – as mentioned above – a fraction of the head
and neck cancers - which similarly to cervical cancer is
induced by Human Papillomavirus (HPV). In addition,
Kaposi Sarcoma induced by Epstein Barr Virus, adult T-
cell leukemia induced by Human T-Lymphotropic virus and
Merkel cell carcinoma induced by Merkel cell polyomavirus
[33] are viral induced cancers. Worldwide, the WHO Inter-
national Agency for Research on Cancer estimated that in
2002 17.8 % of human cancers were caused by infection,
with 11.9 % being caused by one of seven different viruses
[79]. The importance of this is that these cancers might be
easily prevented through vaccination (as recently developed
for human papilloma virus), diagnosed with simple blood
tests, and treated with less-toxic antiviral compounds. How-
ever, when the cancer has developed virus particles are no
longer formed, and the anti-viral agents are by itself ineffi-
cient to combat the cancer – still therapeutic strategies for
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immunological recognition of the integrated oncogenes of
viral origin may still be very relevant. For several of these
cancers immune reactivity and immune-infiltration is asso-
ciated with favourable clinical outcome, well in line with the
observation that most virus-induced cancers develop prefer-
entially in immune suppressed individuals.
Cervical cancer induced by human papillomavirus infec-
tion is the most frequently observed virus induced cancer. T
cell infiltration to cervical cancer with higher CD8/CD4
ratio and higher CD8/Treg ratio is correlated with absence
of lymph node metastasis in patients with large early-stage
cervical cancer, and even further supported by the presence
of a strong systemic anti-vial T cell response [83]. One of
the cell-types affecting T cell infiltration in cervical cancer is
the tumor associated macrophages, shown to induce regula-
tory phenotype characterized by IL10 production and Foxp3
expression in both CD4 and CD8 T cells. Furthermore, the
tumor associated macrophages reduced the antigen-specific
effector functions and led to decreased T-cell infiltration
[64]. Along this line, CXCL12 expression in cervical cancer
is associated with increased infiltration of Foxp3 positive T
cells and correlates with disease progression [53]. Further-
more, as for tumor infiltrating lymphocytes in many indica-
tions CD8 T cells infiltrating cervical cancer is frequently
expressing the inhibitory molecule PD-1, indicating that
these patients could benefit from PD-1 blockade [56]. In-
deed, therapeutic vaccination therapy seems to benefit
patients with HPV-associated neoplastic lesions [58, 113],
and immunotherapy has great clinical promise for HPV
induced cervical cancer.
For the more recently discovered virus induced cancer,
Merkel Cell Carcinoma (Feng et al., 2008), a clear correlation
between CD8 T-cell infiltration to tumor lesions and favorable
clinical outcome has been established, indicating a role for host
T-cells in recognition of tumor cells [80]. Also for this cancer
virus specific Tcells has been identified in cancer patients [52],
and clinic strategies to boost these T cell responses and im-
prove infiltration is likely to benefit clinical outcome.
In general the group of virus-induced cancers are very
attractive in terms of immunotherapy and especially adop-
tive T cell therapy as defined foreign antigens are expressed
by these cancers, allowing for clear distinguish in immune
recognition of healthy and malignant tissue.
Concluding Remarks and Perspectives
A tumor is a very complex structure, and as evident from
this review not only the type of infiltrating cells are impor-
tant by also the location, and moreover the specific pheno-
type and function of that cells in the particular environment.
This is a major challenge for our understanding of lympho-
cyte infiltration and the impact on clinical outcome.
Furthermore signatures of infiltration differ between differ-
ent cancer types – and it is likely that infiltration patterns are
as heterogeneous as recently observed for the mutation
pattern in RCC. There seems to be a consensus that CD8
infiltration is a good prognostic marker in most malignan-
cies analysed – however the impact of CD8 T cells on
clinical outcome may differ and is difficult to quantify.
New initiatives like the immunoscore assessment will
enable us to better understand this impact.
Lymphocyte infiltration has gained increasing interest
with the approval/testing of anti-CTLA4, PD1, and PD-L1
antibodies, as these may not only put a block on immune
suppression but also influence the microenvironment to in-
crease T-cell infiltration. Clinical efficacy of these therapies is
likely to depend on the ability to induce T-cell infiltration –
and as a potential biomarker for response it will likely be
critical to evaluate these criteria in future therapeutic trials.
The new developments in the field; immunoscope, ACT
based on TIL, as well as of the use of antibodies to unleash
T cell reactivity to tumors bring hope that increased insight
into the complex cellular and molecular interactions in the
tumor will pave the way for development of new treatment
strategies that build on the biological characteristics of the
tumor microenviroment.
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Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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